Nasal Drug Delivery Contract

News Release

1 September 2011

Consort Medical plc

Bespak wins its first nasal drug delivery contract

Consort Medical plc (LSE: CSRT), today announces that its Bespak Division has won a contract to develop a nasal drug delivery device for a major unnamed global pharmaceutical company, for an undisclosed application. The device is intended to launch in 2015.

Consort Medical's Bespak Division is a world leader in drug delivery devices and has historically focused on the respiratory and autoinjector markets. The award of this new contract is another signal that Bespak Innovations, our new innovations centre based in Cambridge, is delivering on the Company's strategy to diversify its core competencies of design and high volume manufacture of medical devices into adjacent market areas.

Jon Glenn, CEO of Consort Medical, said:

"We are delighted to announce our first nasal development contract. With programmes in autoinjectors, Point of Care diagnostics and now nasal applications, Bespak is developing a broad suite of products in new growth markets, de-risking the portfolio."

For enquiries, please contact:

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).